Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib

Model scores of the 29,894 trials active now.

Model score 15% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (927 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-02-29. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: heartgreaterventricularmyocardialinfarction
  Phrases that lowered it: myelomamultiplebortezomibcontainingdexamethasone
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 5.3% (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 29.0% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Phase: 3 (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 10 (raises risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 95.2% (raises risk) · Drug's FDA history
• Drug's FAERS reports in the prior 12 months: 10872 (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports before start: 43651 (lowers risk) · Drug's FDA history
• Sponsor's past trials: 19 (lowers risk) · Sponsor's track record
• Number of arms: 2 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma NCT00813150 · started 2009 · scored riskier than 64% of active trials completed
• Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD NCT00908232 · started 2008 · scored riskier than 72% of active trials completed
• Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma NCT01478048 · started 2011 · scored riskier than 58% of active trials completed
• A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma NCT00872521 · started 2009 · scored riskier than 55% of active trials completed
• Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance NCT02467010 · started 2008 · scored riskier than 52% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.